T3D Therapeutics, an Alzheimer’s Disease-Focused Company, Selected to Present at the SEBIO Investor and Partnering Forum

Share Article

T3D Therapeutics will introduce T3D-959, a transformational new drug therapy in development for the treatment of Alzheimer's disease.

T3D Therapeutics, an Alzheimer’s disease-focused drug development company based in North Carolina, announced today it has been selected to be a presenter at the 15th annual Southeast BIO Investor & Partnering Forum taking place November 5-7, 2013 at the Jefferson Hotel in Richmond, VA. SEBIO showcases a select group of emerging life sciences and medical technology companies from the southeastern US. T3D Therapeutics will speak about T3D-959, its new potential disease-remedial therapy in development for the treatment of Alzheimer’s disease.

"We are honored to have been chosen by the Selection Committee to present alongside an array of highly regarded new companies," said John Didsbury, Ph.D., Founder and CEO of T3D Therapeutics. "Unlike single dimension therapies in development that target one pathology, T3D-959 acts in a multi-dimensional manner with the potential to improve multiple Alzheimer’s disease pathologies, thus providing the prospect of slowing, stopping or reversing the course of this devastating disease with our drug therapy."

About T3D Therapeutics

T3D Therapeutics Inc. is a privately-held Research Triangle Park, NC-based company incorporated in 2013 ( http://www.t3dtherapeutics.com ). The company is committed to develop and commercialize disease remedial therapeutics for the treatment of Alzheimer’s disease and other CNS disorders. T3D-959 (DB959), its lead product candidate, has successfully concluded Phase 1 clinical trials. The company is supported by expert advisors including Dr. Lawrence Friedhoff who was responsible for the development and launch of Aricept®, the market leading drug for treating Alzheimer’s disease and Dr. Warren Strittmatter. Dr. Strittmatter is recognized for his ground-breaking research in Alzheimer’s and Huntington’s disease. He received the Alzheimer’s Association Zenith Award and was recognized by the Institute for Scientific Information as the “Top 20 Scientists” in Neuroscience and Behavior for the decade 1992-2002.

About SEBIO Investor & Partnering Forum

Recognized as the Southeast region's premier life sciences and medical technology investor conference, this event connects emerging companies with potential investors and partners in a forum that provides meaningful networking opportunities. A testament to the quality of our companies, SEBIO's past presenting companies have raised more than $2.5 billion collectively in private and public funding since the inaugural conference in 1999.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

John Didsbury
Visit website